Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

{
  "signal_id": "b1af4802-ed31-b414-b13d-3122515c17dc",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-23T05:15:00+00:00",
  "company": {
    "name": "Roche",
    "domain": "roche.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/23/3367081/0/en/positive-interim-data-shows-roche-s-sefaxersen-significantly-reduces-proteinuria-in-people-with-iga-nephropathy-igan.html",
    "title": "Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)",
    "excerpt": "Basel, 23 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR). Proteinuria is a key indicator of kidney damage and a reduction in UPCR is strongly associated with the preservation of long-term kidney function. 5,6 Sefaxersen is a once-monthly subcutaneous injection designed to enable self-administration for people with IgAN. The safety and tolerability profile of sefaxersen was consistent with previously reported data, with no new safety signals identified.",
    "product": "sefaxersen",
    "summary": "Roche announced positive interim results from its phase III IMAgINATION study for its investigational drug sefaxersen, which met its primary endpoint of significantly reducing proteinuria in adults with IgA nephropathy (IgAN).",
    "location": "Basel, Switzerland",
    "planning": true,
    "confidence": 0.9,
    "product_data": {
      "name": "sefaxersen",
      "full_text": "investigational sefaxersen",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-09-23T05:15:00Z",
    "location_data": [
      {
        "city": "Basel",
        "state": "Basel-Stadt",
        "region": "Western Europe",
        "country": "Switzerland",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-23",
    "article_sentence": "Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN)."
  }
}

curl https://signals.autobound.ai/v1/signals/b1af4802-ed31-b414-b13d-3122515c17dc \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"roche.com","limit":20}'